

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. **AU 2013286177 B2**

(54) Title  
**Use of long-acting GLP-1 peptides**

(51) International Patent Classification(s)  
**A61K 38/26** (2006.01) **A61P 3/10** (2006.01)  
**A61P 3/04** (2006.01) **A61P 5/50** (2006.01)

(21) Application No: **2013286177** (22) Date of Filing: **2013.06.21**

(87) WIPO No: **WO14/005858**

(30) Priority Data

(31) Number	(32) Date	(33) Country
<b>12174535.0</b>	<b>2012.07.01</b>	<b>EP</b>
<b>61/708,162</b>	<b>2012.10.01</b>	<b>US</b>
<b>61/694,837</b>	<b>2012.08.30</b>	<b>US</b>
<b>12186781.6</b>	<b>2012.10.01</b>	<b>EP</b>

(43) Publication Date: **2014.01.09**

(44) Accepted Journal Date: **2018.04.26**

(71) Applicant(s)  
**Novo Nordisk A/S**

(72) Inventor(s)  
**Jensen, Christine Bjorn;Rasmussen, Mads Frederik;Zdravkovic, Milan;Kristensen, Peter**

(74) Agent / Attorney  
**Shelston IP Pty Ltd., Level 21, 60 Margaret Street, Sydney, NSW, 2000, AU**

(56) Related Art  
**Clinical Trial NCT00696657, entitled "A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide," pp. 1-5 (3/11/2015) at URL [clinicaltrials.gov/archive/NCT00696657/2011\\_03\\_25](http://clinicaltrials.gov/archive/NCT00696657/2011_03_25)**  
**WO 2011138421 A1**  
**S. MADSBAD ET AL, "An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future", DIABETES, OBESITY AND METABOLISM, (20110324), vol. 13, no. 5, pages 394 - 407**  
**WO 2010092163 A2**